MedTrace Logo

An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes

NCT03216564 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2018-09-06

No results posted yet for this study

Summary

Diabetic kidney disease (nephropathy) develops in nearly 40% of patients with type 2 diabetes mellitus. Diabetic nephropathy is caused by damage to the small blood vessels in the kidneys due to uncontrolled blood sugar levels, which mean that the kidneys become less effective at filtering urine. This is associated with albuminuria (protein in the urine). Treatment with some drugs reduces the loss of albumin through the urine and delays disease progression. There is increasing evidence that vitamin D could also be important in management of diabetic kidney disease. The aim of this study is to investigate the efficacy and safety of a combined regimen of calcitriol (active vitamin D) and established drugs for diabetic kidney disease.

Conditions

  • Diabetic Nephropathies

Interventions

DRUG

Calcitriol

Active vitamin D (Calcitriol) 0.25 micrograms

Sponsors & Collaborators

  • Weill Cornell Medical College in Qatar

    collaborator OTHER

  • Hamad Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Muhammad Asim, MB BS · Hamad Medical Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-10
Primary Completion
2019-05-10
Completion
2019-05-10

Countries

  • Qatar

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03216564 on ClinicalTrials.gov